Literature DB >> 24448687

Utilization of liquid chromatography mass spectrometry analyses to identify LKB1-APC interaction in modulating Wnt/β-catenin pathway of lung cancer cells.

Shu-Fang Jian1, Chang-Chun Hsiao, Shin-Yi Chen, Ching-Chieh Weng, Tzu-Lei Kuo, Deng-Chyang Wu, Wen-Chun Hung, Kuang-Hung Cheng.   

Abstract

UNLABELLED: STK11/LKB1, a serine/threonine protein kinase and tumor suppressor, is a key upstream kinase of adenine monophosphate-activated protein kinase, which is a kinase involved in controlling cell polarity and maintaining cellular energy homeostasis. LKB1 is mutated in a significant number of Peutz-Jeghers syndrome (PJS) cases and sporadic cancers, and is most frequently mutated in lung adenocarcinomas; however, little is known about how LKB1 is involved in lung cancer progression. In this study, immunoprecipitation-HPLC tandem mass spectrometry (IP-LC-MS/MS) was performed to identify novel proteins interacting with LKB1 in lung cancer. Interestingly, many LKB1-interacting proteins acquired from the LC-MS/MS approach were mapped, using MetaCore pathway analysis, to the cystic fibrosis transmembrane conductance regulator activation pathway. Moreover, it was determined that LKB1 directly interacts with APC, and this LKB1-APC interaction was further confirmed by reverse immunoprecipitation assays, but GSK3β was dispensable for the association of LKB1 and APC. Importantly, LKB1 binds to APC to suppress the Wnt/β-catenin signaling pathway, which is known to be involved in cell proliferation and migration. Subsequent analysis of the downstream targets of the Wnt/TCF pathway led to the identification of several Wnt-regulated genes, such as CD44, COX-2, survivin, and c-Myc, whose expression levels are downregulated by LKB1. In summary, these results demonstrate that LKB1 regulates the Wnt pathway through a direct interaction with APC to suppress the tumorigenic/metastatic potential of lung tumors. IMPLICATIONS: LKB1 status influences the molecular circuitry (Wnt/β-catenin pathway), cellular biology, and may serve as a potential therapeutic node in genetically defined subsets of lung cancer. Mol Cancer Res; 12(4); 622-35. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24448687     DOI: 10.1158/1541-7786.MCR-13-0487

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  5 in total

1.  Inhibition of β-Catenin Activity Abolishes LKB1 Loss-Driven Pancreatic Cystadenoma in Mice.

Authors:  Mei-Jen Hsieh; Ching-Chieh Weng; Yu-Chun Lin; Chia-Chen Wu; Li-Tzong Chen; Kuang-Hung Cheng
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

2.  Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.

Authors:  Jinghan Wang; Keqiang Zhang; Jinhui Wang; Xiwei Wu; Xiyong Liu; Bin Li; Yan Zhu; Yong Yu; Qingbao Cheng; Zhenli Hu; Chao Guo; Shuya Hu; Bing Mu; Chun-Hao Tsai; Jie Li; Lynne Smith; Lu Yang; Qi Liu; Peiguo Chu; Vincent Chang; Baihe Zhang; Mengchao Wu; Xiaoqing Jiang; Yun Yen
Journal:  Oncotarget       Date:  2015-08-07

3.  Tear Proteomics Study of Dry Eye Disease: Which Eye Do You Adopt as the Representative Eye for the Study?

Authors:  Ming-Tse Kuo; Po-Chiung Fang; Shu-Fang Kuo; Alexander Chen; Yu-Ting Huang
Journal:  Int J Mol Sci       Date:  2021-01-03       Impact factor: 5.923

4.  Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients.

Authors:  Laura Boldrini; Mirella Giordano; Marco Lucchi; Franca Melfi; Gabriella Fontanini
Journal:  Biomed Rep       Date:  2018-07-02

Review 5.  Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application.

Authors:  Yuan-Xiang Shi; De-Qiao Sheng; Lin Cheng; Xin-Yu Song
Journal:  J Oncol       Date:  2019-12-12       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.